Moreover, Liu et al. demonstrated that the role of VISTA was nonredundant with the PD-1/PD-L1 pathway in terms of controlling T cell activation and that the combinatorial blockade of VISTA and PD-L1 achieved optimal tumour-eradicating therapeutic efficacy in colon cancer models. This evidence concerns the gene VSIR and neoplasm.